|
Aldesleukin
drug data and news
Aldesleukin drug data, resources, and news articles (when available). Onconews.org provides news on cancer research. This section, which includes profiles on medicines that may or not be cancer-related is in beta form. If things run smoothly we will be releasing a new format late in the summer of 2006.
| Generic name |
Aldesleukin
|
| Brand Names/Synonyms |
Interleukin-2 precursor;IL-2;T-cell growth factor;TCGF; Proleukin (Chiron Corp) |
| Indication |
For treatment of adults with metastatic renal cell carcinoma |
|
Sponsored links
|
|
Description |
Proleukin, a lymphokine, is produced by recombinant DNA technology using a genetically engineered E. coli strain containing an analog of the human interleukin-2 gene. Genetic engineering techniques were used to modify the human IL-2 gene, and the resulting expression clone encodes a modified human interleukin-2. This recombinant form differs from native interleukin-2 in the following ways: a) PROLEUKIN is not glycosylated because it is derived from E. coli ; b) the molecule has no N-terminal alanine; the codon for this amino acid was deleted during the genetic engineering procedure; c) the molecule has serine substituted for cysteine at amino acid position 125. |
| Pharmacology |
Used to treat renal cell carcinoma, proleukin induces the enhancement of lymphocyte mitogenesis and stimulation of long-term growth of human interleukin-2 dependent cell lines, the enhancement of lymphocyte cytotoxicity, the induction of killer cell (lymphokine-activated (LAK) and natural (NK)) activity; and the induction of interferon-gamma production. IL-2 is normally produced by the body, secreted by T cells, and stimulates growth and differentiation of T cell response. It can be used in immunotherapy to treat cancer. It enhances the ability of the immune system to kill tumor cells and may interfere with blood flow to the tumor. |
| Mechanism Of Action |
Proleukin binds to the IL-2 receptor which leads to heterodimerization of the cytoplasmic domains of the IL-2R beta and gamma(c) chains, activation of the tyrosine kinase Jak3, and phosphorylation of tyrosine residues on the IL-2R beta chain. These events led to the creation of an activated receptor complex, to which various cytoplasmic signaling molecules are recruited and become substrates for regulatory enzymes (especially tyrosine kinases) that are associated with the receptor. These events stimulate growth and differentiation of T cells. |
Aldesleukin News
(When available) |
|
| Dosage Forms |
POWDER FOR SOLUTION |
| Drug_Category |
Antineoplastic Agents |
| Absorption |
Not Available |
| Interactions |
Not Available |
| Toxicity |
Not Available |
| Organisms Affected |
Humans and other mammals |
| Chemical IUPAC Name |
Human interleukin 2 (modified) |
| Chemical Formula |
C690H1115N177O202S6 |
| Molecular Weight |
15314.8 |
| Smiles String |
Not Available |
| Melting Point |
Not Available |
| Water Solubility |
Not Available |
| State |
Transparent, slightly viscous, aqueous liquid |
| LogP/Hphobicity |
-0.192 |
| Isoelectric Point |
7.31 |
| Biotransformation |
Not Available |
| Half Life |
13 min-85 min |
| Protein Binding [%] |
Not Available |
| RxList Link |
RXlist |
|
Sponsored links
|
|
| Drug Reference |
http://www.rxlist.com/cgi/generic2/aldesleukin.htm |
| Drug Type |
Approved Drug |
| Accession No |
BIOD00082 |
| CAS Registry Number |
85898-30-2 |
| KEGG Compound ID |
Not Available |
| PubChem ID |
Not Available |
| PharmGKB ID |
PA448081 |
| SwissProt ID |
IL2_HYLLA (P60569) |
| GenBank ID |
M11144 |
| Drug ID Number [DIN] |
2130181
|
|
|
